According to SurgePays's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.54697. At the end of 2023 the company had a P/S ratio of 0.6692.
Year | P/S ratio | Change |
---|---|---|
2023 | 0.6692 | -1.06% |
2022 | 0.6763 | 41.71% |
2021 | 0.4773 | 73.83% |
2020 | 0.2746 | -76.95% |
2019 | 1.19 | -45.74% |
2018 | 2.19 | -95.27% |
2017 | 46.4 | 900.06% |
2016 | 4.64 | -47.6% |
2015 | 8.85 | -91.72% |
2014 | 107 | 18.99% |
2013 | 89.8 | |
2011 | 518 | 2104.42% |
2010 | 23.5 | -92.66% |
2009 | 320 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 3.90 | 612.96% | ๐บ๐ธ USA |
Novartis NVS | 4.12 | 652.44% | ๐จ๐ญ Switzerland |
Stryker Corporation SYK | 6.20 | 1,033.40% | ๐บ๐ธ USA |
Cooper Companies COO | 4.94 | 803.02% | ๐บ๐ธ USA |
STAAR Surgical STAA | 6.11 | 1,017.83% | ๐บ๐ธ USA |
CONMED CNMD | 1.85 | 237.81% | ๐บ๐ธ USA |
Integra LifeSciences IART | 1.59 | 190.09% | ๐บ๐ธ USA |